This clinical trial is focused on studying the treatment of Multiple Myeloma, a type of cancer that affects plasma cells in the bone marrow. The study will explore the effectiveness of adding Isatuximab to a treatment regimen that includes Lenalidomide, Bortezomib, and Dexamethasone. Isatuximab is given as a solution for infusion, while Lenalidomide is taken orally in capsule form, and Bortezomib is administered as an injection. Dexamethasone is provided in tablet form.
The purpose of the study is to assess whether the addition of Isatuximab improves treatment outcomes for patients with newly diagnosed Multiple Myeloma. Participants will receive a combination of these medications over a period of time, with some receiving a placebo instead of Isatuximab. The study will monitor the patients’ response to the treatment, focusing on how well the cancer is controlled and how long patients remain free from disease progression.
Throughout the study, patients will undergo regular assessments to track their health and the effectiveness of the treatment. These assessments will help determine the best approach to managing Multiple Myeloma and improving patient outcomes. The trial aims to provide valuable insights into the potential benefits of combining these medications for treating this type of cancer.
Germany 
